NuCana (NCNA) Competitors $1.09 +0.03 (+2.83%) Closing price 02/21/2025 03:58 PM EasternExtended Trading$1.06 -0.03 (-2.75%) As of 02/21/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends NCNA vs. TSBX, EDSA, PBM, BFRI, AYTU, CYCN, CELZ, AIM, DWTX, and INDPShould you be buying NuCana stock or one of its competitors? The main competitors of NuCana include Turnstone Biologics (TSBX), Edesa Biotech (EDSA), Psyence Biomedical (PBM), Biofrontera (BFRI), Aytu BioPharma (AYTU), Cyclerion Therapeutics (CYCN), Creative Medical Technology (CELZ), AIM ImmunoTech (AIM), Dogwood Therapeutics (DWTX), and Indaptus Therapeutics (INDP). These companies are all part of the "pharmaceutical products" industry. NuCana vs. Turnstone Biologics Edesa Biotech Psyence Biomedical Biofrontera Aytu BioPharma Cyclerion Therapeutics Creative Medical Technology AIM ImmunoTech Dogwood Therapeutics Indaptus Therapeutics NuCana (NASDAQ:NCNA) and Turnstone Biologics (NASDAQ:TSBX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation, profitability and community ranking. Does the media favor NCNA or TSBX? In the previous week, NuCana's average media sentiment score of 0.00 equaled Turnstone Biologics'average media sentiment score. Company Overall Sentiment NuCana Neutral Turnstone Biologics Neutral Which has more risk & volatility, NCNA or TSBX? NuCana has a beta of 0.96, indicating that its share price is 4% less volatile than the S&P 500. Comparatively, Turnstone Biologics has a beta of 2.12, indicating that its share price is 112% more volatile than the S&P 500. Do insiders and institutionals hold more shares of NCNA or TSBX? 44.0% of NuCana shares are held by institutional investors. Comparatively, 52.5% of Turnstone Biologics shares are held by institutional investors. 31.2% of NuCana shares are held by insiders. Comparatively, 32.1% of Turnstone Biologics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has better earnings & valuation, NCNA or TSBX? NuCana has higher earnings, but lower revenue than Turnstone Biologics. Turnstone Biologics is trading at a lower price-to-earnings ratio than NuCana, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuCanaN/AN/A-$34.37M-$10.48-0.10Turnstone Biologics$19.31M0.47-$55.20M-$3.24-0.12 Do analysts recommend NCNA or TSBX? NuCana currently has a consensus target price of $25.00, indicating a potential upside of 2,193.58%. Turnstone Biologics has a consensus target price of $0.45, indicating a potential upside of 15.80%. Given NuCana's stronger consensus rating and higher probable upside, equities research analysts plainly believe NuCana is more favorable than Turnstone Biologics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NuCana 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Turnstone Biologics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Does the MarketBeat Community favor NCNA or TSBX? NuCana received 247 more outperform votes than Turnstone Biologics when rated by MarketBeat users. Likewise, 67.65% of users gave NuCana an outperform vote while only 44.44% of users gave Turnstone Biologics an outperform vote. CompanyUnderperformOutperformNuCanaOutperform Votes25167.65% Underperform Votes12032.35% Turnstone BiologicsOutperform Votes444.44% Underperform Votes555.56% Is NCNA or TSBX more profitable? Turnstone Biologics' return on equity of -105.99% beat NuCana's return on equity.Company Net Margins Return on Equity Return on Assets NuCanaN/A -314.47% -112.60% Turnstone Biologics N/A -105.99%-87.27% SummaryNuCana and Turnstone Biologics tied by winning 7 of the 14 factors compared between the two stocks. Get NuCana News Delivered to You Automatically Sign up to receive the latest news and ratings for NCNA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NCNA vs. The Competition Export to ExcelMetricNuCanaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.88M$7.04B$5.77B$8.98BDividend YieldN/A2.87%4.78%3.85%P/E Ratio-0.106.1326.4618.82Price / SalesN/A311.27456.6780.61Price / CashN/A67.8344.0437.47Price / Book0.126.747.634.64Net Income-$34.37M$138.11M$3.18B$245.69M7 Day Performance19.78%-2.43%-1.91%-2.66%1 Month Performance-1.80%-1.91%-0.19%-2.15%1 Year Performance-87.17%-5.03%16.70%12.90% NuCana Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NCNANuCana2.9692 of 5 stars$1.09+2.8%$25.00+2,193.6%-86.8%$2.80MN/A0.0030TSBXTurnstone Biologics1.5347 of 5 stars$0.41+6.0%$0.45+8.8%-84.1%$9.56M$19.31M-0.1382EDSAEdesa Biotech2.6731 of 5 stars$2.69-17.2%$21.00+680.7%-53.9%$9.33MN/A-1.3920Earnings ReportGap UpHigh Trading VolumePBMPsyence BiomedicalN/A$1.40+9.0%N/A-97.0%$9.21MN/A0.00N/APositive NewsBFRIBiofrontera2.6492 of 5 stars$1.18+0.9%$7.00+493.2%+13.6%$9.14M$35.36M-0.5270News CoveragePositive NewsAYTUAytu BioPharma1.0333 of 5 stars$1.39+0.4%N/A-55.0%$8.52M$81M-1.13160High Trading VolumeCYCNCyclerion Therapeutics0.7875 of 5 stars$3.12+3.0%N/A-1.1%$8.46M$1.62M0.0030Negative NewsGap DownCELZCreative Medical Technology0.902 of 5 stars$4.74+3.3%N/A+28.0%$8.30M$10,000.00-1.255Gap UpHigh Trading VolumeAIMAIM ImmunoTech1.9945 of 5 stars$0.13-6.9%$2.75+2,031.8%-67.1%$8.23M$200,000.00-0.2720High Trading VolumeDWTXDogwood TherapeuticsN/A$6.13-8.6%N/AN/A$8.15MN/A-0.945Gap DownINDPIndaptus Therapeutics3.1124 of 5 stars$0.80+2.1%$8.50+963.8%-52.9%$8.15MN/A-0.476Gap Up Related Companies and Tools Related Companies Turnstone Biologics Competitors Edesa Biotech Competitors Psyence Biomedical Competitors Biofrontera Competitors Aytu BioPharma Competitors Cyclerion Therapeutics Competitors Creative Medical Technology Competitors AIM ImmunoTech Competitors Dogwood Therapeutics Competitors Indaptus Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NCNA) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredHow to trade Executive Order 14154Trump’s pen must be running out of ink… Since he returned to office he’s signed more than 50 Executive Orde...Porter & Company | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | SponsoredWarning: China Launches AI Attack on AmericaIf you have any money in AI stocks, pay attention because... According to Louis Navellier, the legendary in...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NuCana plc Please log in to your account or sign up in order to add this asset to your watchlist. Share NuCana With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NCNA Stock Alerts